: iStockAnalyst.com Symbols Feed

Amylin Pharmaceuticals (NASDAQ: AMLN): Upgraded To Overweight At Barclays, Target Raised To $22

Tue, 24 Nov 2009 12:33:02 GMT

Barclays is upgrading Amylin Pharmaceuticals (NASDAQ:AMLN) to Overweight from Equal-Weight with a $22 price target (prev. $16). According to the firm, AMLN shares have been under pressure for several years, which they attribute to concerns regarding flattening Byetta trends, increasing competitive visibility, perceived regulatory risk for exenatide LAR, excess cash burn and limited pipeline visibility.[More...]

Diabetes Care: Global Investing Opportunities

Mon, 23 Nov 2009 03:23:59 GMT

The American Diabetes Association estimates that there are currently 23.6 million diabetics in the U.S. (7.8% of the total population, including 17.9 million diagnosed cases, 5.7 million undiagnosed, and 57 million pre-diabetics. Diabetes results in an estimated $174 billion in costs from diagnosed cases of diabetes in the U.S. (2007).[More...]

Innovative Drug Companies Headline The Gainers

Mon, 02 Nov 2009 20:44:13 GMT

For all the debate about possible reform to the U.S. medical system, it is easy to forget that the majority of major innovations in drugs and medical devices come from America. It is worth remembering that even with all the problems troubling the health care system, innovation continues to be a bright spot. Three of the biggest gains among individual stocks on Monday were from U.S. companies in the pharmaceutical sector largely because of this sort of innovation.[More...]

Pharmaceuticals & Biotech - Industry Outlook

Tue, 09 Jun 2009 12:05:35 GMT

The pharmaceutical industry is entering a period of substantial change in 2009. Most of the names in the industry are facing significant patent challenges in the years to come. U.S.-based firms are facing foreign exchange headwinds, as well. Revenue growth is non-existent, and earnings growth is being driven primarily by mergers, cost-cutting and share buybacks. Knowing that investors rarely pay-up for this type of manufactured earnings growth, we struggle to see a broad-based out-performance for the large-cap pharmaceutical sector in 2009. Valuations, however, are attractive, with several of the largest players trading at PEs below 10x, including: Pfizer (PFE, 7.5x), Eli Lilly (LLY,[More...]

Biogen And Icahn: Call It A Draw And Get Back To Business

Wed, 03 Jun 2009 21:45:30 GMT

Proxy battles are all the rage these days. On the heels of a major proxy battle between Bill Ackman and Target (TGT) last week (Ackman Missed His Target), the results of the fight between Biogen Idec (BIIB) and Carl Icahn appears to have ended in a draw. Icahn, a well known activist investor, was trying to get four board members elected to BIIB’s Board of Directors, and after preliminary results were released it appears that two of them were elected in[More...]

Carl Icahn V. Amylin Pharmacueticals Inc.

Mon, 20 Apr 2009 22:11:25 GMT

Normally I’d say woe to the CEO who crosses notoriously active investor Carl Icahn, but this time he might have met his match. Yes, other executives may have fallen to his ummm… persistent nature, but biotech Amylin Pharmaceuticals Inc. (Nasdaq: AMLN) lead independent director James Wilson, is having none of it. Along with strong shareholder Eastbourne Capital Management, Icahn has repeatedly attempted to stir up trouble at the company with the intent of changing the board of directors more to his liking. In Icahn’s case at least, the ultimate goal is to Amylin to sell itself to its diabetes drug partner Eli Lilly & Co. (NYSE: LLY). And as usual, he’s made no secret about his intentions. Then again, neither has[More...]

Biotech Churns Out Big Returns In Bull And Bear Markets

Mon, 06 Apr 2009 16:41:18 GMT

Editor’s Note: Marc Lichtenfeld is the Director of Research of Access Research Group and a Senior Analyst for the Xcelerated Profits Report. As investors begin to look more and more toward... Money Morning is here to help investors profit handsomely on this seismic shift in the global economy. Money moves markets. But Money Morning lets you move first. [More...]

Roche Keeps M&A Party Rolling With $46.8 Billion Deal For Genentech

Fri, 13 Mar 2009 14:34:00 GMT

By Don Miller Associate Editor Money Morning Big Pharma’s rapidly accelerating consolidation pattern snowballed yesterday (Thursday) as Roche Holding AG (ADR: RHHBY) struck a deal to... Money Morning is here to help investors profit handsomely on this seismic shift in the global economy. Money moves markets. But Money Morning lets you move first. [More...]

Pharmaceuticals

Tue, 10 Feb 2009 18:38:00 GMT

Large pharmaceutical companies all seem to be in a similar boat heading into 2009. Most of the names in the industry are facing significant patent challenges in the years to come. U.S.-based firms are facing foreign exchange headwinds as well. Revenue growth is non-existent, and earnings growth is being driven primarily by cost-cutting and share buybacks. Knowing that investors rarely pay-up for this type of manufactured earnings growth, we struggle to see a broad-based out-performance for the large-cap pharmaceutical sector in 2009. Valuations, however, are attractive, with several of the largest players trading at PEs below 10x, including Pfizer (PFE, 7x), Eli Lilly (LLY, 9x), Merck ([More...]

Biotech Breakout - Amylin Pharmaceuticals, Inc.

Thu, 05 Feb 2009 01:27:00 GMT

Last night we said that biotechs were poised to breakout and they delivered. AMLN, ALXN, [More...]

FDA: Byetta drug label is revised

Mon, 02 Nov 2009 20:00:00 GMT

FDA: Byetta drug label is revised[More...]

Domain Raises $500M Life Sciences Fund

Tue, 11 Aug 2009 19:52:00 GMT

Aug. 11--CARMEL VALLEY -- Domain Associates LLC has raised a $500 million venture capital fund to be invested exclusively in life science companies.
It is the eighth fund raised by Domain Associates, which has invested in numerous local companies.
Domain is based in Princeton, N.J., with West Coast headquarters in Carmel Valley.

: iStockAnalyst.com Symbols Feed

Amylin Pharmaceuticals (NASDAQ: AMLN): Upgraded To Overweight At Barclays, Target Raised To $22

Diabetes Care: Global Investing Opportunities

Innovative Drug Companies Headline The Gainers

Pharmaceuticals & Biotech - Industry Outlook

Biogen And Icahn: Call It A Draw And Get Back To Business

Carl Icahn V. Amylin Pharmacueticals Inc.

Biotech Churns Out Big Returns In Bull And Bear Markets

Roche Keeps M&A Party Rolling With $46.8 Billion Deal For Genentech

Pharmaceuticals

Biotech Breakout - Amylin Pharmaceuticals, Inc.

FDA: Byetta drug label is revised

Domain Raises $500M Life Sciences Fund

Amylin Pharmaceuticals Q2 Net Loss Narrows

Citigroup, Wells Fargo, Boeing are big movers

Why Clean Tech Is Taking Biotech's Shine

The Fortune Financial Undertakes Review of Stocks in the Healthcare and Services Sectors

Asterand Announces Agreement to Acquire BioSeek

Amylin Pharmaceuticals Board of Directors Elects Paulo F. Costa Chairman of the Board

Amylin Pharmaceuticals Reports Second Quarter Financial Results

Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study

Amylin Pharmaceuticals to Webcast Second Quarter Results

Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity

New Drug Application for Exenatide Once Weekly Accepted for Review by FDA

Amylin Pharmaceuticals to Present at Piper Jaffray Europe Conference

Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009

Form 4 AMYLIN PHARMACEUTICALS For: Oct 02 Filed by: SULLIVAN JOSEPH P (10K)

Form 4 CLARK PAUL N For: Oct 02 (10K)

Form 4 BECK TERESA For: Oct 02 (10K)

Form 4 ALTMAN STEVEN R For: Oct 02 (10K)

Form 4 GAVIN JAMES R III For: Oct 02 (10K)

Form 4 EASTHAM KARIN For: Oct 02 (10K)

Form 4 AMYLIN PHARMACEUTICALS For: Sep 16 Filed by: EASTBOURNE CAPITAL MANAGEMENT LLC/CA (10K)

Form 4 Denner Alexander J For: Jun 09 (10K)

Form 3 Denner Alexander J For: Jun 09 (10K)

Form 4 ADAMS ADRIAN For: May 27 (10K)